On January 16, 2026, ZYLOXTB (02190) announced that the company (as the buyer) entered into a sale and purchase agreement with E-Med Solutions (as the seller). Under the agreement, the buyer agreed to acquire a 49% equity interest in the target company, Optimed Holding GmbH, for a total consideration of approximately €18.375 million. The agreement also grants the buyer an option, exercisable at its discretion, to acquire the remaining equity in the target company from its other shareholders. Following the completion of the proposed acquisition, the target company will not become a subsidiary of ZYLOXTB, and its financial results will not be consolidated into the company's financial statements.
The target group is primarily engaged in the development, manufacturing, and distribution of medical technology products, instruments, and solutions. Within the target group, Optimed Medizinische Instrumente GmbH, a wholly-owned subsidiary of the target company, serves as its main operating subsidiary. Headquartered in Ettlingen, Germany, this company is dedicated to the research, development, manufacturing, and global distribution of high-quality medical products for minimally invasive vascular and urological surgeries. Optimed boasts the most comprehensive product portfolio in the peripheral venous stent market, including specialized devices for the iliofemoral vein, iliac artery bifurcation, inferior vena cava, and aorta.
The Board of Directors believes the acquisition will deliver the following benefits to the company: It marks a significant milestone in the company's long-term commitment to global expansion. Serving as a crucial step in its strategy to enter European and global markets, the acquisition will accelerate ZYLOXTB's international strategic deployment through the integration of these assets. This move will diversify the company's product portfolio, expand its global distribution network, and significantly enhance its competitive position and influence on the international stage.
The integration of the company's and Optimed's sales networks will build a unified global commercial platform, accelerating the worldwide adoption of innovative vascular solutions. With a broader and more diverse product portfolio, the company is well-positioned to expand into markets outside mainland China. A key element of this strategy involves leveraging Optimed's deep collaborative relationships with European medical experts to accelerate clinical processes and drive successful product commercialization.
The transaction is expected to generate significant manufacturing and operational synergies between Germany and China. By integrating advanced production capabilities, the company will continuously improve overall product quality and operational efficiency. ZYLOXTB will continue to utilize the target company's strong brand recognition in Europe while strategically expanding its manufacturing capacity in Germany, ensuring a robust, reliable, and efficient supply for Europe and other key international markets.
The company's integrated global commercial platform will empower and fully unleash the group's highly efficient research and development capabilities. By extending its innovations from the domestic market to the global stage, ZYLOXTB is committed to consistently providing cutting-edge, high-quality medical solutions for patients and healthcare professionals worldwide. Post-acquisition, the company and the target company will fully integrate their commercial platforms, including sales and marketing networks, market development capabilities, and customer service infrastructure.
The target company will act as the exclusive distributor for all of ZYLOXTB's vascular products in markets outside mainland China. Rüdiger Hausherr will continue to serve as the Chief Executive Officer of Optimed and will report to the company's Chairman and CEO, Dr. Zhao Zhong. This strategic arrangement is expected to significantly enhance and accelerate the company's international sales capabilities and global expansion pace.
